<DOC>
	<DOCNO>NCT02694068</DOCNO>
	<brief_summary>Peritoneal Dialysis ( PD ) technique treat kidney failure fluid instill body 's peritoneal cavity . Fluid solutes travel across peritoneal membrane , function membrane critical successful PD . Studies show certain demographic clinical variable explain small part variability baseline function . This study explore common genetic variant determine baseline peritoneal membrane function patient start treatment PD change function upon treatment . This study incorporate data subject ' first ever peritoneal equilibrium test ( PET ) , change transfer water across peritoneal membrane time , demographic information , result laboratory analysis DNA , blood , dialysate . The investigator hope study provide information biological pathway account variability peritoneal membrane . This could ultimately lead development biomarkers identify individual risk decline peritoneal membrane function time and/or use identify novel therapeutic target preserve enhance membrane function . Identifying biological pathway also increase understand vascular biology , angiogenesis , fibrosis could apply tissue disease .</brief_summary>
	<brief_title>Biological Determinants Peritoneal Dialysis</brief_title>
	<detailed_description>This study comprise patient population pre-existing biorepositories prospectively enrolled subject . DNA analyze cohort data DNA already collect available , prospective site collect plasma , DNA , spend dialysate analysis . Clinical data related subject ' first ever Peritoneal Equilibrium Test ( PET ) , demographic information , change ultrafiltration capacity time , correlate various genetic marker interest . Blood dialysate collect first study visit , additional sample collection . These sample collect part PET standard care study visit , time 4 hour dwell 2.5 % 4.25 % dextrose solution . Annually , subject either undergo PET standard care perform additional 4 hour dwell part study . These subsequent measure utilized determine change ultrafiltration capacity time . This study two specific aim : Aim 1 : To identify validate genetic locus influence peritoneal solute transfer rate ( PSTR ) start PD . Aim 2 : To identify validate genetic locus pre-specified biologic pathway change peritoneal ultrafiltration capacity . If subject grant permission , Genome Wide Association Studies ( GWAS ) result may transfer NIH database genotype phenotype ( dbGaP ) . Additionally , subject may agree remain sample maintain University Washington Kidney Research Institute repository use future research study .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Adults age 20 able provide consent Record PET within 6 month start PD treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Peritoneal Dialysis</keyword>
	<keyword>Genetic</keyword>
	<keyword>Peritoneal Membrane</keyword>
	<keyword>Peritoneal Equilibrium Test</keyword>
	<keyword>Ultrafiltration Capacity</keyword>
	<keyword>End Stage Renal Disease ( ESRD )</keyword>
</DOC>